See the DrugPatentWatch profile for keytruda

Keytruda, a drug developed by Merck & Co., received its initial FDA approval for the treatment of advanced melanoma [1]. This approval was granted in September 2014 [1]. Keytruda, also known as pembrolizumab, is a type of immunotherapy that helps the body's immune system fight cancer cells [1].

According to DrugPatentWatch.com, Keytruda has several patents protecting its composition of matter, methods of use, and formulation [1]. These patents extend into the 2030s, providing Merck & Co. with a significant period of market exclusivity for this indication [1].

It is important to note that Keytruda has since received additional FDA approvals for the treatment of other types of cancer, including non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high (MSI-H) cancer [1].

Sources:

1. [DrugPatentWatch.com - Keytruda (pembrolizumab)](https://www.drugpatentwatch.com/drugs/keytruda)